Jazz Pharmaceuticals plc Quarterly Costs and Expenses in USD from Q1 2018 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Total costs of sales and operating expenses for the period.
Summary
Jazz Pharmaceuticals plc quarterly/annual Costs and Expenses history and growth rate from Q1 2018 to Q3 2024.
  • Jazz Pharmaceuticals plc Costs and Expenses for the quarter ending September 30, 2024 was $795M, a 0.62% decline year-over-year.
  • Jazz Pharmaceuticals plc Costs and Expenses for the twelve months ending September 30, 2024 was $3.34B, a 7.15% decline year-over-year.
  • Jazz Pharmaceuticals plc annual Costs and Expenses for 2023 was $3.26B, a 12.6% decline from 2022.
  • Jazz Pharmaceuticals plc annual Costs and Expenses for 2022 was $3.72B, a 27.4% increase from 2021.
  • Jazz Pharmaceuticals plc annual Costs and Expenses for 2021 was $2.92B, a 47.3% increase from 2020.
Costs and Expenses, Trailing 12 Months (USD)
Costs and Expenses, Quarterly (USD)
Costs and Expenses, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $3.34B $795M -$4.99M -0.62% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 $3.35B $824M +$24.7M +3.09% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-01
Q1 2024 $3.32B $836M +$69M +9% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-02
Q4 2023 $3.26B $889M -$346M -28% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-28
Q3 2023 $3.6B $800M -$116M -12.7% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 $3.72B $800M -$47.7M -5.62% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-01
Q1 2023 $3.77B $767M +$40.6M +5.59% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-02
Q4 2022 $3.72B $1.24B +$388M +45.8% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-28
Q3 2022 $3.34B $916M +$106M +13.1% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 $3.23B $847M +$25.9M +3.16% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 $3.2B $726M +$281M +63% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 $2.92B $847M +$355M +72.2% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-28
Q3 2021 $2.57B $810M +$405M +100% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 $2.16B $821M +$457M +125% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-03
Q1 2021 $1.71B $445M -$279M -38.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q4 2020 $1.99B $492M -$28.4M -5.46% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-01
Q3 2020 $2.01B $405M +$82K +0.02% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 $2.01B $364M +$34.5M +10.4% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-03
Q1 2020 $1.98B $724M +$350M +93.5% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-04
Q4 2019 $1.63B $520M +$229M +78.6% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-01
Q3 2019 $1.4B $405M +$124M +44.2% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-02
Q2 2019 $1.28B $330M -$17.4M -5.02% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-04
Q1 2019 $1.29B $374M +$17.6M +4.94% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-05
Q4 2018 $1.28B $291M Oct 1, 2018 Dec 31, 2018 10-K 2021-02-23
Q3 2018 $281M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-05
Q2 2018 $347M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-06
Q1 2018 $357M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-07
* An asterisk sign (*) next to the value indicates that the value is likely invalid.